Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Kin Liam

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Respirology Case Reports|June 23, 2023
Pathological complete response in an advance stage IIIB non-small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literatureChun Ian Soo, Diana Bee-Lan Ong, Ka Kiat Chin, et al.
Thoracic Cancer|May 3, 2022
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited countrySoon Hin How, Lye Mun Tho, Chong Kin Liam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final AnalysisChong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studiesYi-Long Wu, Victor Lee, Chong-Kin Liam, et al.
Translational Lung Cancer Research|March 18, 2024
Does dose reduction of afatinib affect treatment outcomes of patients with <i>EGFR</i>-mutant metastatic non-small cell lung cancer in real-world clinical practice?Mau Ern Poh, Chee Shee Chai, Chong Kin Liam, et al.
BMC Cancer|September 11, 2019
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational studyGwo-Fuang Ho, Chee-Shee Chai, Adlinda Alip, et al.
Cancer Management and Research|June 23, 2022
Outcomes of Patients with <i>EGFR-</i>Mutant Advanced NSCLC in a Developing Country in Southeast AsiaSoon Hin How, Chong Kin Liam, Muhammad Adil Zainal Abidin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Lung Cancer Screening in Asia: An Expert Consensus ReportDavid Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, et al.
Scientific Reports|July 16, 2024
Post-discharge spirometry evaluation in patients recovering from moderate-to-critical COVID-19: a cross-sectional studyChee-Shee Chai, Muhammad Amin Bin Ibrahim, Nur Amira Binti Azhar, et al.
Clinical Lung Cancer|September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Respirology Case Reports|June 23, 2023
Pathological complete response in an advance stage IIIB non-small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literatureChun Ian Soo, Diana Bee-Lan Ong, Ka Kiat Chin, et al.
Thoracic Cancer|May 3, 2022
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited countrySoon Hin How, Lye Mun Tho, Chong Kin Liam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final AnalysisChong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studiesYi-Long Wu, Victor Lee, Chong-Kin Liam, et al.
Translational Lung Cancer Research|March 18, 2024
Does dose reduction of afatinib affect treatment outcomes of patients with <i>EGFR</i>-mutant metastatic non-small cell lung cancer in real-world clinical practice?Mau Ern Poh, Chee Shee Chai, Chong Kin Liam, et al.
BMC Cancer|September 11, 2019
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational studyGwo-Fuang Ho, Chee-Shee Chai, Adlinda Alip, et al.
Cancer Management and Research|June 23, 2022
Outcomes of Patients with <i>EGFR-</i>Mutant Advanced NSCLC in a Developing Country in Southeast AsiaSoon Hin How, Chong Kin Liam, Muhammad Adil Zainal Abidin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Lung Cancer Screening in Asia: An Expert Consensus ReportDavid Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, et al.
Scientific Reports|July 16, 2024
Post-discharge spirometry evaluation in patients recovering from moderate-to-critical COVID-19: a cross-sectional studyChee-Shee Chai, Muhammad Amin Bin Ibrahim, Nur Amira Binti Azhar, et al.
Clinical Lung Cancer|September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.
Pageof 9